Search Results - "Vauleon, E"

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial by Tao, Y., Biau, J., Sun, X.S., Sire, C., Martin, L., Alfonsi, M., Prevost, J.B., Modesto, A., Lafond, C., Tourani, J.M., Miroir, J., Kaminsky, M.C., Coutte, A., Liem, X., Chautard, E., Vauleon, E., Drouet, F., Ruffier, A., Ramee, J.F., Waksi, G., Péchery, A., Wanneveich, M., Guigay, J., Aupérin, A., Bourhis, J.

“…To evaluate potential synergistic effect of pembrolizumab with radiotherapy (RT) compared with a standard-of-care (SOC) cetuximab–RT in patients with locally…”
Get full text

Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series by Castelli, J., Feuvret, L., Haoming, Q. C., Biau, J., Jouglar, E., Berger, A., Truc, G., Gutierrez, F. Llamas, Morandi, X., Le Reste, P. J., Thillays, F., Loussouarn, D., Nouhaud, E., Crehange, G., Antoni, D., Vauleon, E., de Crevoisier, R., Noel, G.

“…The aims of this multicentre retrospective study were to identify prognostic or therapeutic factors impacting on overall survival in patients with gliosarcoma…”
Get full text

P11.61 Development of a novel preclinical GBM model and therapeutic impact of IRE1 inhibition by Le Reste, P, Pineau, R, Jouan, F, Samal, J, Jegou, G, Patterson, J, Vauleon, E, Avril, T, Pandit, A, Chevet, E

“…Abstract Glioblastoma Multiforme (GBM) is the most severe primary brain tumor and represents more than 15% of all brain tumors. Despite an aggressive treatment…”
Get full text

Adaptive radiotherapy in head and neck cancer is required to avoid tumor underdose by Castelli, J, Simon, A, Rigaud, B, Chajon, E, Thariat, J, Benezery, K, Vauleon, E, Jegoux, F, Henry, O, Lafond, C, de Crevoisier, R

Get more information

Endoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers by Avril, T, Vauléon, E, Chevet, E

“…The unfolded protein response (UPR) is an adaptive cellular program used by eukaryotic cells to cope with protein misfolding stress. During tumor development,…”
Get full text

PO-0661: Gliosarcoma: prognostic and therapeutics factors by Castelli, J, Feuvret, L, Haoming, Q, Biau, J, Jouglar, E, Berger, A, Truc, G, Guttierrez, F. Llama, Morandi, X, Thillays, F, Loussouarn, D, Lecouillard, I, Crehange, G, Antoni, D, Vauleon, E, De Crevoisier, R, Noë, G

Get full text

PO-0642: Nomograms to assess the parotid gland dose in head and neck IMRT based on anatomical markers by Castelli, J, Simon, A, Rigaud, B, Henry, O, Chajon, E, Haigron, P, Ospina Arango, J.D, Vauleon, E, Benezery, K, De Crevoisier, R

Get full text

Chemoradiotherapy for cancer of the esophagus: contribution of the leucovorin, 5-fluorouracil bolus, and infusion-cisplatin-radiotherapy schedule starting with two neoadjuvant chemotherapy cycles: results from a pilot study by Tran Vuong, T. N., Le Prisé, E., Vauléon, E., Boucher, E., Audrain, O., Raoul, J.-L.

“…SUMMARY To assess feasibility and tolerance of a modification in the usual radiochemotherapy regimen for esophageal cancer by using a leucovorin,…”
Get full text

Parameters Impacting on Late Rectal Toxicity in 3D Conformal Radiotherapy for Prostate Cancer by Chira, C.I, Lahbabi, K, Le Prisé, E, Vincendeau, S, Vauleon, E, Bossi, A, Bayat, S, Rossille, D, Manens, J, de Crevoisier, R

Get full text

Parameters Impacting on Late Bladder Toxicity in Prostate Cancer 3D Conformal Radiotherapy by Le Prisé, E, Chira, C.I, Lahbabi, K, Bossi, A, Vincendeau, S, Vauleon, E, Rossille, D, Bayat, S, Lafond, C, de Crevoisier, R

Get full text

CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas by Appay, Romain, Dehais, Caroline, Maurage, Claude-Alain, Alentorn, Agusti, Carpentier, Catherine, Colin, Carole, Ducray, François, Escande, Fabienne, Idbaih, Ahmed, Kamoun, Aurélie, Marie, Yannick, Mokhtari, Karima, Tabouret, Emeline, Trabelsi, Nesrine, Uro-Coste, Emmanuelle, Delattre, Jean-Yves, Figarella-Branger, Dominique

“…The 2016 World Health Organization (WHO) classification of central nervous system tumors stratifies isocitrate dehydrogenase (IDH)-mutant gliomas into 2 major…”
Get full text

1589 Workshops for caregivers of patients treated for brain tumors by Vauléon, E, Larible, C, Lecouillard, I, Nouhaud, E, Castelli, J, Pelotte, E, Chiffoleau, A, Lebrun, F

Get full text

465P Larotracking: Real-life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program by Dufresne, A., Huillard, O., Dalban, C., Geier, M., Wassermann, J., Zanetta, S., Cabourg, M., Catargi, B., El Kouri, C., Hrab, I., Laramas, M., Moreira, A., Saada, E.B., Tournigand, C., Valentin, T., Vauleon, E., Mayet, R., Perol, D., Blay, J-Y.

Get full text

OS7.7 Educational program for caregivers of patients with brain tumors: AGAPE by Bourien, H, Larible-Lefort, C, Pelotte, E, Le Brun, F, Vauleon, E

“…Abstract BACKGROUND Patients with brain tumors suffer from physical, neurocognitive, and psychological decline. Among the potential evolutions of the disease,…”
Get full text

Clinical Outcomes of Patients with Lung Cancer Treated with Radiation Therapy Andanti-PD-1 Therapy: A Multicenter Retrospective Analysis From GFPC Group by Lesueur, P., Escande, A., Thariat, J., Lerouge, D., Danhier, S., Monnet, I., Vauleon, E., Cortot, A., Chouaïd, C., Gervais, R.

Get full text

KS04.7.A HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION by Boele, F W, Frances, S M, Darlix, A, Ducray, F, Tabouret, E, Burger, M C, Ryden, I, Malmstrom, A, Vauleon, E, Kazda, T, Renovanz, M, Werner, J, Welsh, L, Sanghera, P, Dehais, C, Desideri, I, McBain, C, Mehta, S, Lord, H, Jena, R, Foweraker, K, Ashkan, K, Engelhardt, J, Bourg, V, Herrlinger, U, Lawson McLean, A, Hertler, C, Haldbo-Classen, L, Dahlrot, R H, Noel, G, Durando, X, Hrab, I, Razis, E, Muhic, A, Klein, M

“…Abstract BACKGROUND Patients with IDH-mutant, 1p/19-codeleted oligodendroglioma have a relatively favourable prognosis and can experience long periods of…”
Get full text

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma by Kacimi, Salah Eddine O, Dehais, Caroline, Feuvret, Loïc, Chinot, Olivier, Carpentier, Catherine, Bronnimann, Charlotte, Vauleon, Elodie, Djelad, Apolline, Cohen-Jonathan Moyal, Elizabeth, Langlois, Olivier, Campone, Mario, Ducloie, Mathilde, Noel, Georges, Cuzzubbo, Stefania, Taillandier, Luc, Ramirez, Carole, Younan, Nadia, Menei, Philippe, Dhermain, Frédéric, Desenclos, Christine, Ghiringhelli, François, Bourg, Veronique, Ricard, Damien, Faillot, Thierry, Appay, Romain, Tabouret, Emeline, Nichelli, Lucia, Mathon, Bertrand, Thomas, Alice, Tran, Suzanne, Bielle, Franck, Alentorn, Agusti, Iorgulescu, J Bryan, Boëlle, Pierre-Yves, Labreche, Karim, Hoang-Xuan, Khê, Sanson, Marc, Idbaih, Ahmed, Figarella-Branger, Dominique, Ducray, François, Touat, Mehdi

“…Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3 ) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the…”
Get full text

KS02.5.A OVERALL SURVIVAL ASSOCIATED WITH FIRST-LINE PCV OR TEMOZOLOMIDE IN COMBINATION WITH RADIOTHERAPY IN PATIENTS WITH IDH-MUTANT, 1P/19Q CODELETED, GRADE 3 OLIGODENDROGLIOMA: ANALYSIS FROM THE POLA COHORT by Kacimi, S E O, Dehais, C, Carpentier, C, Chinot, O, Bronnimann, C, Vauleon, E, Djelad, A, Moyal, E C, Campone, M, Ducloie, M, Noel, G, Cuzzubbo, S, Thaillandier, L, Ramirez, C, Colin, C, Appay, R, Tabouret, E, Nichelli, L, Mathon, B, Thomas, A, Tran, S, Bielle, F, Alentor, A, Labreche, K, Idbaih, A, Figarella-Branger, D, Ducray, F, Touat, M

“…Abstract BACKGROUND Patients with IDH-mutant, 1p/19q codeleted, grade 3 oligodendroglioma (Olig-3) derive benefit from the addition of alkylating agent…”
Get full text

LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial by Bourhis, J., Sire, C., Tao, Y., Martin, L., Alfonsi, M., Prevost, J.B., Rives, M., Lafond, C., Tourani, J.M., Biau, J., Geoffrois, L., Coutte, A., Liem, X., Vauleon, E., Drouet, F., Pechery, A., Guigay, J., Wanneveich, M., Aupérin, A., Sun, X.

Get full text

Beneath HMGA2 alterations in pleomorphic adenomas: Pathological, immunohistochemical, and molecular insights by Lépine, Charles, Descotes, Françoise, Pissaloux, Daniel, Tirode, Franck, Lopez, Jonathan, Philouze, Pierre, Fieux, Maxime, Wassef, Michel, Castain, Claire, Uro-Coste, Emmanuelle, Babin, E., Bach, C., Badoual, C., Baglin, A.C., Bastit, V., Baujat, B., Bensadoun, R.J., Benzerdjeb, N., Bernadach, M., Bozec, L., Grayeli, A.Bozorg, Camby, S., Cassagnau, E., Castelli, J., Chevalier, D., Clatot, F., Constans, J.M., Coste, A., Coste, F., Costes, V., Cottier, J.P., Cristofari, J.P., Cupissol, D., Delgrande, J., Delord, J.P., Digue, L., Dolivet, G., Doré, M., Dufour, X., Eker, E., Even, C., Fabiano, E., Faivre, S., Fakhry, N., Frandon, J., de Gabory, L., Garcier, M., Guihard, S., Halimi, C., Herman, P., Hourseau, M., Jankowski, R., Jeanne, C., Juliéron, M., Kreps, S., Laccoureye, L., Lae, M., Lagarde, F., Lagrange, A., Lamuraglia, M., Lapeyre, M., Cardon, A.Lasne, Lefevre, M., Lelonge, Y., Liem, X., Linassier, C., Maingon, P., Michel, J., Mineur, G., Mirghani, H., Modesto, A., Molinier-Blossier, S., Morinière, S., Moya-Plana, A., Musat, E., Nguyen, F., Obongo-Anga, F.R., Page, C., Pestre, J., Pons, C., J.-M.Prades, Queiros, C., Rambeau, A., Ramin, L., Siegfried, A., Righini, C.A., Saada, E., Salas, S., Simonaggio, A., Sterkers, O., Xu-Shan, S., Taouachi, R., Tassart, M., David, M. Timar, Coste, E. Uro, Valette, G., Varoquaux, A., Vauleon, E., Vulquin, N., Wassef, M.

“…Most salivary gland neoplasms are distinguished by specific recurrent gene fusions. Recently, a subset of pleomorphic adenomas (PAs) originated from the…”
Get full text